These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 14625255)

  • 1. Combinations of targeted therapies take aim at multiple pathways.
    Goldman B
    J Natl Cancer Inst; 2003 Nov; 95(22):1656-7. PubMed ID: 14625255
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current screening for molecular target therapy of cancer].
    Shiotsu Y
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1863-72. PubMed ID: 14650952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. As targeted therapies evolve, challenges remain.
    Benowitz S
    J Natl Cancer Inst; 2004 Mar; 96(5):351-2. PubMed ID: 14996855
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of bortezomib on the drug sensitivity of imatinib resistant K562/G01 cells].
    Zhou Y; Ma LM; Li XY; Zhang HP; Wang T; Niu YY; Ren RR
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):392-5. PubMed ID: 21781497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.
    Dasmahapatra G; Nguyen TK; Dent P; Grant S
    Leuk Res; 2006 Oct; 30(10):1263-72. PubMed ID: 16481037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib: paradigm or anomaly?
    Druker BJ
    Cell Cycle; 2004 Jul; 3(7):833-5. PubMed ID: 15254412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances of molecular targeted agents: opportunities for imaging.
    Dancey JE
    Cancer Biol Ther; 2003; 2(6):601-9. PubMed ID: 14688462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of bortezomib on reverse multidrug resistance and XIAP expression in imatinib-resistant primary cells of chronic myeloid leukemia in blastic crisis].
    Zhao J; Ma LM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):899-904. PubMed ID: 23998582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New agents in cancer clinical trials.
    Adams J; Elliott PJ
    Oncogene; 2000 Dec; 19(56):6687-92. PubMed ID: 11426656
    [No Abstract]   [Full Text] [Related]  

  • 10. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
    Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
    Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic lethality: killing cancer with cancer.
    Garber K
    J Natl Cancer Inst; 2002 Nov; 94(22):1666-8. PubMed ID: 12441317
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
    Kinsella P; Howley R; Doolan P; Clarke C; Madden SF; Clynes M; Farrell M; Amberger-Murphy V
    Exp Cell Res; 2012 Mar; 318(5):641-52. PubMed ID: 22285130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Problems in the current target therapy of malignancies].
    Stukov AN; Gershanovich ML; Filov VA; Imianitov EN
    Vopr Onkol; 2005; 51(5):607-11. PubMed ID: 16756022
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
    Pédeboscq S; L'Azou B; Passagne I; De Giorgi F; Ichas F; Pometan JP; Cambar J
    J Exp Ther Oncol; 2008; 7(2):99-111. PubMed ID: 18771084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
    Wang Q; Zhou HS; Huang KK; Jiang XJ; Wu FQ; Cao R; Yin CX; Liao LB; Zheng ZX; He H; Lin R; Yi ZS; Xu D; Yang M; Meng FY
    Int J Oncol; 2012 Feb; 40(2):418-26. PubMed ID: 22002244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
    Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
    Yang X; Yang L; Gong YP; Chang H; Zhou RQ; Xing HY; Zheng BH
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):793-6. PubMed ID: 21302443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurological adverse effects caused by cytotoxic and targeted therapies.
    Schiff D; Wen PY; van den Bent MJ
    Nat Rev Clin Oncol; 2009 Oct; 6(10):596-603. PubMed ID: 19707193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate in cutaneous melanoma.
    Redondo P; Lloret P; Andreu EJ; Inoges S
    J Invest Dermatol; 2004 Dec; 123(6):1208-9. PubMed ID: 15610538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.